AstraZeneca (NASDAQ:AZN) is one of the 8 Best Inexpensive Stocks to Buy Right Now. On June 9, the first patient was dosed by ...

WILMINGTON, Del., June 02, 2025--Positive results from the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab demonstrated a highly statistically ...

A Brit woman was given a shocking diagnosis of stage 4 breast cancer after she said her tumour was repeatedly dismissed as ...

June brought major breast cancer updates, and CURE is sharing the latest treatment combinations, biomarker-driven care and ...

Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

ENHERTU® Plus Pertuzumab Reduced the Risk of Disease Progression or Death by 44% Versus THP as First-Line Therapy in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast09 ...

ENHERTU® Reduced the Risk of Death by 30% Versus Ramucirumab Plus Paclitaxel as a Second-Line Therapy in Patients with HER2 Positive Unresectable or Metastatic Gastric Cancer in DESTINY ...

Lea Hughes first noticed a small lump on her right breast aged 29 - but was told she had 'lumpy boobs' due to hormones.

Lea first spotted a small lump on her right breast but was reassured her 'lumpy boobs' were just due to hormones ...

FOR years, doctors told Lea Hughes that her common cancer symptom was simply caused by hormones – now she has tumours in her ...

AstraZeneca (LSE:AZN) recently announced the U.S. FDA accelerated approval of Datroway for treating advanced EGFR-mutated non ...

A woman was diagnosed with incurable stage 4 breast cancer after her tumour was dismissed as 'lumpy boobs' for two years. Lea ...